USA - NASDAQ:ECOR - US28531P2020 - Common Stock
The current stock price of ECOR is 4.97 USD. In the past month the price decreased by -2.17%. In the past year, price decreased by -23.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.76 | 236.77B | ||
ISRG | INTUITIVE SURGICAL INC | 54.5 | 157.27B | ||
BSX | BOSTON SCIENTIFIC CORP | 34.57 | 144.96B | ||
SYK | STRYKER CORP | 29.33 | 144.07B | ||
MDT | MEDTRONIC PLC | 17.19 | 121.96B | ||
BDX | BECTON DICKINSON AND CO | 13.11 | 53.61B | ||
IDXX | IDEXX LABORATORIES INC | 54.63 | 52.49B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.95 | 43.69B | ||
RMD | RESMED INC | 28.61 | 40.00B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 16.08 | 34.20B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.52 | 27.05B | ||
DXCM | DEXCOM INC | 39.68 | 26.45B |
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
ELECTROCORE INC
200 Forge Way, Suite 205
Rockaway NEW JERSEY 07866 US
CEO: Daniel S. Goldberger
Employees: 73
Phone: 19732900097
The current stock price of ECOR is 4.97 USD. The price decreased by -0.5% in the last trading session.
The exchange symbol of ELECTROCORE INC is ECOR and it is listed on the Nasdaq exchange.
ECOR stock is listed on the Nasdaq exchange.
10 analysts have analysed ECOR and the average price target is 21.5 USD. This implies a price increase of 332.63% is expected in the next year compared to the current price of 4.97. Check the ELECTROCORE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELECTROCORE INC (ECOR) has a market capitalization of 37.67M USD. This makes ECOR a Nano Cap stock.
ELECTROCORE INC (ECOR) currently has 73 employees.
ELECTROCORE INC (ECOR) has a support level at 4.83 and a resistance level at 5.61. Check the full technical report for a detailed analysis of ECOR support and resistance levels.
The Revenue of ELECTROCORE INC (ECOR) is expected to grow by 22.37% in the next year. Check the estimates tab for more information on the ECOR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ECOR does not pay a dividend.
ELECTROCORE INC (ECOR) will report earnings on 2025-11-11, after the market close.
ELECTROCORE INC (ECOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
The outstanding short interest for ELECTROCORE INC (ECOR) is 9.49% of its float. Check the ownership tab for more information on the ECOR short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ECOR. While ECOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ECOR reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 26.03% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -91.02% | ||
ROE | -1190.57% | ||
Debt/Equity | 0 |
10 analysts have analysed ECOR and the average price target is 21.5 USD. This implies a price increase of 332.63% is expected in the next year compared to the current price of 4.97.
For the next year, analysts expect an EPS growth of -4.2% and a revenue growth 22.37% for ECOR